LifeStance Health Group filings document the company's outpatient mental healthcare business, Nasdaq-listed common stock and public-company governance. Its 8-K reports furnish quarterly and annual results, Regulation FD presentations, operating metrics, cash flow commentary and capital allocation disclosures.
The filing record also covers proxy matters, director elections, executive compensation, officer and board changes, equity incentive awards, share repurchase authorization, and common stock offering documents under shelf registration statements. These disclosures describe governance structure, securities registration, material agreements, stockholder selling activity, repurchases, and the risks and reporting obligations associated with LifeStance's virtual and in-person outpatient care model.
LifeStance Health Group, Inc. reported that Chief Medical Officer Stephanie Carin Eken acquired equity-based compensation in the form of restricted stock units. On March 5, 2026, she was granted 115,107 RSUs, each representing a contingent right to receive one share of LifeStance common stock.
The Form 4 classifies this as a grant or award acquisition at a price of $0.00 per share, typical for stock-based compensation. Following this grant, her directly held common stock and RSU-related interest totals 115,107 shares of LifeStance common stock on a contingent basis.
LifeStance Health Group, Inc. officer Ryan Pardo reported equity award activity in the company’s common stock. On March 5, 2026, he acquired 129,496 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock.
On March 6, 2026, 21,854 shares were withheld at $6.93 per share to cover tax obligations related to vested RSUs. The filing specifies that these withheld shares reduce the shares issued to him and do not constitute any open‑market sale.
After these transactions, he held 1,023,377 shares directly and 2,551,520 shares indirectly through the Kimberly Pardo Irrevocable Trust, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
LifeStance Health Group, Inc. reported insider equity activity by its Chief Executive Officer, David Bourdon. On March 5, 2026, he acquired 395,683 shares of common stock through a grant of restricted stock units, with each RSU representing the right to receive one common share.
On March 6, 2026, 65,837 shares of common stock were withheld by the company at a price of $6.93 per share to cover tax obligations from vested RSUs. The footnote explains this was a tax-withholding disposition and did not involve any open-market sale of shares.
LifeStance Health Group director Kenneth A. Burdick reported a tax-related share withholding tied to vested restricted stock units. On March 6, 2026, the issuer withheld 424,551 shares of common stock at $7.11 per share to cover tax obligations, which the filing states is not an open-market sale. After this net settlement, Burdick directly holds 3,012,020 shares and indirectly holds 46,511 shares through Burdick Family LLC.
Paunovich Vukasin reported acquisition or exercise transactions in this Form 4 filing.
LifeStance Health Group, Inc. Chief Technology Officer Vukasin Paunovich was granted 86,331 shares of common stock in the form of restricted stock units (RSUs) on March 5, 2026. Each RSU represents a right to receive one share of common stock, increasing his directly held stake to 264,902 shares after the award.
LifeStance Health Group, Inc. reported that officer Lisa K. Miller received an equity grant of 107,914 restricted stock units on March 5, 2026. Each RSU represents a contingent right to receive one share of common stock.
On March 6, 2026, 21,590 shares of common stock were withheld by the company at $6.93 per share to cover tax obligations related to vested RSUs. The footnote states this was not an open-market sale but a reduction in shares issued upon settlement. After these transactions, Miller directly held 330,577 shares of common stock.
LifeStance Health Group, Inc. Chief People Officer Ann Varanakis reported two equity transactions in company common stock. On March 5, 2026, she acquired 86,331 restricted stock units as a grant, each representing a contingent right to receive one share of common stock.
On March 6, 2026, 21,566 shares were withheld by the company at a price of $6.93 per share to cover tax obligations upon settlement of vested RSUs. The footnote states this withholding reduced shares delivered to her and did not involve any open‑market sale.
LifeStance Health Group executive Ryan McGroarty reported an equity award of company stock. On March 5, 2026, he acquired 179,856 shares of common stock through a grant at a price of $0.00 per share, described as restricted stock units where each unit represents one share of common stock. Following this award, his directly held common stock holdings increased to 727,611 shares, including the newly granted RSUs, which vest into actual shares subject to their terms.
LifeStance Health Group, Inc. reported a large insider-related transaction involving entities affiliated with TPG. On March 2, 2026, an entity indirectly associated with the reporting persons completed an open-market sale of 20,685,061 shares of common stock at $7.01 per share. Following this sale, 140,026,557 shares of LifeStance common stock were reported as indirectly owned. According to the disclosures, the shares are directly held by TPG VIII Lynnwood Holdings Aggregation, L.P., and the reporting persons may be deemed to beneficially own the securities only to the extent of their respective pecuniary interests, which they expressly disclaim beyond that.
Entities affiliated with Summit Partners and associated with LifeStance Health Group director Darren M. Black sold 4,314,939 shares of LifeStance common stock in an open-market transaction at $7.01 per share. After these sales, the Summit-managed funds collectively held 29,209,776 LifeStance shares.